Long-term nicotine treatment decreases striatal alpha 6* nicotinic acetylcholine receptor sites and function in mice
- PMID: 15681595
- DOI: 10.1124/mol.104.006429
Long-term nicotine treatment decreases striatal alpha 6* nicotinic acetylcholine receptor sites and function in mice
Abstract
Alpha-conotoxin MII-sensitive nicotinic acetylcholine receptors (nAChRs) are distinct from other subtypes in their relatively restricted localization to the striatum and some other brain regions. The effect of nicotine treatment on nAChR subtypes has been extensively investigated, with the exception of changes in alpha-conotoxin MII-sensitive receptor expression. We therefore determined the consequence of long-term nicotine administration on this subtype and its function. Nicotine was given in drinking water to provide a long-term yet intermittent treatment. Consistent with previous studies, nicotine exposure increased 125I-epibatidine and 125I-A85380 (3-[2-(S)-azetidinylmethoxy]pyridine), but not 125I-alpha-bungarotoxin, receptors in cortex and striatum. We observed an unexpected reduction (30%) in striatal 125I-alpha-conotoxin MII sites, which occurred because of a decrease in B(max). This decline was more robust in older (>8-month-old) compared with younger (2-4-month-old) mice, suggesting age is important for nicotine-induced disruption of nAChR phenotype. Immunoprecipitation experiments using nAChR subunit-directed antibodies indicate that alterations in subunit-immunoreactivity with nicotine treatment agree with those in the receptor binding studies. To determine the relationship between striatal nAChR sites and function, we measured nicotine-evoked [3H]dopamine release. A decline was obtained with nicotine treatment that was caused by a selective decrease in alpha-conotoxin MII-sensitive but not alpha-conotoxin MII-resistant dopamine release. These results may explain previous findings that nicotine treatment decreased striatal nAChR-mediated dopamine function, despite an increase in [3H]nicotine (alpha4*) sites. The present data suggest that the alpha6* nAChR subtype represents a key factor in the control of dopamine release from striatum, which adapts to long-term nicotine treatment by down-regulation of alpha6* receptor sites and function.
Similar articles
-
Loss of nicotinic receptors in monkey striatum after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment is due to a decline in alpha-conotoxin MII sites.Mol Pharmacol. 2002 Jan;61(1):230-8. doi: 10.1124/mol.61.1.230. Mol Pharmacol. 2002. PMID: 11752225
-
Differential declines in striatal nicotinic receptor subtype function after nigrostriatal damage in mice.Mol Pharmacol. 2003 May;63(5):1169-79. doi: 10.1124/mol.63.5.1169. Mol Pharmacol. 2003. PMID: 12695545
-
Differential regulation of mesolimbic alpha 3/alpha 6 beta 2 and alpha 4 beta 2 nicotinic acetylcholine receptor sites and function after long-term oral nicotine to monkeys.J Pharmacol Exp Ther. 2006 Jul;318(1):381-8. doi: 10.1124/jpet.106.104414. Epub 2006 Apr 18. J Pharmacol Exp Ther. 2006. PMID: 16622038
-
The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum.Biochem Pharmacol. 2007 Oct 15;74(8):1235-46. doi: 10.1016/j.bcp.2007.07.032. Epub 2007 Jul 27. Biochem Pharmacol. 2007. PMID: 17825262 Free PMC article. Review.
-
Striatal alpha6* nicotinic acetylcholine receptors: potential targets for Parkinson's disease therapy.J Pharmacol Exp Ther. 2006 Feb;316(2):481-9. doi: 10.1124/jpet.105.094375. Epub 2005 Oct 6. J Pharmacol Exp Ther. 2006. PMID: 16210393 Review.
Cited by
-
Beta2-containing nicotinic acetylcholine receptors mediate calcium/calmodulin-dependent protein kinase-II and synapsin I protein levels in the nucleus accumbens after nicotine withdrawal in mice.Eur J Pharmacol. 2013 Feb 15;701(1-3):1-6. doi: 10.1016/j.ejphar.2012.12.005. Epub 2013 Jan 10. Eur J Pharmacol. 2013. PMID: 23313759 Free PMC article.
-
Structural differences determine the relative selectivity of nicotinic compounds for native alpha 4 beta 2*-, alpha 6 beta 2*-, alpha 3 beta 4*- and alpha 7-nicotine acetylcholine receptors.Neuropharmacology. 2010 Jun;58(7):1054-66. doi: 10.1016/j.neuropharm.2010.01.013. Epub 2010 Jan 28. Neuropharmacology. 2010. PMID: 20114055 Free PMC article.
-
Repeated nicotine administration robustly increases bPiDDB inhibitory potency at alpha6beta2-containing nicotinic receptors mediating nicotine-evoked dopamine release.Biochem Pharmacol. 2010 Aug 1;80(3):402-9. doi: 10.1016/j.bcp.2010.03.018. Epub 2010 Mar 25. Biochem Pharmacol. 2010. PMID: 20346923 Free PMC article.
-
Chronic Menthol Does Not Change Stoichiometry or Functional Plasma Membrane Levels of Mouse α3β4-Containing Nicotinic Acetylcholine Receptors.Mol Pharmacol. 2019 Apr;95(4):398-407. doi: 10.1124/mol.118.114769. Epub 2019 Jan 22. Mol Pharmacol. 2019. PMID: 30670481 Free PMC article.
-
Pharmacological and immunochemical characterization of alpha2* nicotinic acetylcholine receptors (nAChRs) in mouse brain.Acta Pharmacol Sin. 2009 Jun;30(6):795-804. doi: 10.1038/aps.2009.68. Acta Pharmacol Sin. 2009. PMID: 19498420 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources